Department of General Practice and Centre for Cancer Research, University of Melbourne, Melbourne, Victoria, Australia.
Epidemiology of Cancer Healthcare & Outcomes (ECHO) Group, Department of Behavioural Science and Health, Institute of Epidemiology and Health Care (IECH), UCL, London, UK.
Cancer Med. 2024 Jul;13(14):e70006. doi: 10.1002/cam4.70006.
Abnormal results in common blood tests may occur several months before lung cancer (LC) and colorectal cancer (CRC) diagnosis. Identifying early blood markers of cancer and distinct blood test signatures could support earlier diagnosis in general practice.
Using linked Australian primary care and hospital cancer registry data, we conducted a cohort study of 855 LC and 399 CRC patients diagnosed between 2001 and 2021. Requests and results from general practice blood tests (six acute phase reactants [APR] and six red blood cell indices [RBCI]) were examined in the 2 years before cancer diagnosis. Poisson regression models were used to estimate monthly incidence rates and examine pre-diagnostic trends in blood test use and abnormal results prior to cancer diagnosis, comparing patterns in LC and CRC patients.
General practice blood test requests increase from 7 months before CRC and 6 months before LC diagnosis. Abnormalities in many APR and RBCI tests increase several months before cancer diagnosis, often occur prior to or in the absence of anaemia (in 51% of CRC and 81% of LC patients with abnormalities), and are different in LC and CRC patients.
This study demonstrates an increase in diagnostic activity in Australian general practice several months before LC and CRC diagnosis, indicating potential opportunities for earlier diagnosis. It identifies blood test abnormalities and distinct signatures that are early markers of LC and CRC. If combined with other pre-diagnostic information, these blood tests have potential to support GPs in prioritising patients for cancer investigation of different sites to expedite diagnosis.
在肺癌 (LC) 和结直肠癌 (CRC) 诊断前数月,常见血液检测结果可能出现异常。识别癌症的早期血液标志物和独特的血液检测特征可支持在一般实践中进行更早的诊断。
使用澳大利亚初级保健和医院癌症登记处的关联数据,我们对 2001 年至 2021 年间诊断的 855 例 LC 和 399 例 CRC 患者进行了队列研究。在癌症诊断前 2 年内,检查了一般实践血液检测(六种急性时相反应物 [APR] 和六种红细胞指数 [RBCI])的请求和结果。使用泊松回归模型估计每月发病率,并检查癌症诊断前血液检测使用和异常结果的预诊断趋势,比较 LC 和 CRC 患者的模式。
CRC 前 7 个月和 LC 前 6 个月,一般实践的血液检测请求增加。许多 APR 和 RBCI 检测的异常在癌症诊断前数月增加,通常在贫血之前或没有贫血时发生(在有异常的 CRC 患者中占 51%,LC 患者中占 81%),并且在 LC 和 CRC 患者中不同。
本研究表明,在 LC 和 CRC 诊断前数月,澳大利亚一般实践中的诊断活动增加,表明有更早诊断的潜力。它确定了血液检测异常和独特特征,这些异常和特征是 LC 和 CRC 的早期标志物。如果与其他预诊断信息相结合,这些血液检测可能有助于 GP 优先考虑不同部位的癌症检查,以加快诊断。